Clinical Trials for Mesothelioma Patients: Pemetrexed, Cisplatin, and Vitamin B12 Study Criteria

Read about the patient criteria for a current clinical trial being conducted to study the effects of Pemetrexed, Cisplatin, and Vitamin B12 for patients who have been diagnosed with mesothelioma. Please note: this information is provided by Weitz & Luxenberg for informational purposes only. At this time, this study is only being conducted in Lille, France.

Patient Characteristics:

Inclusion criteria:

• WHO performance status 0-2

• Life expectancy > 3 months

• Absolute neutrophil count = 1,500/mm^3

• Platelet count = 100,000/mm^3

• Creatinine clearance > 45 mL/min

• Total bilirubin = 1.5 times upper limit of normal (ULN)

• Transaminases = 3 times ULN (5 times ULN if liver metastases)

• Not pregnant or nursing

• Fertile patients of must use effective contraception during and for 6 months after completion of study treatment

Exclusion criteria:

• Hypersensitivity to pemetrexed disodium or any of its excipients

• Peripheral neuropathy = grade 2

• Impossible to receive study therapy due to geographical, social, familial, or psychological reasons

Courtesy of ClinicalTrials.gov.

Other helpful links:

Asbestos Asbestos
Asbestos and lung cancer Asbestos and lung cancer
Mesothelioma attorney Mesothelioma attorney
Mesothelioma Lawyer Mesothelioma lawyer
Asbestos attorney Asbestos attorney